9-FLUORENOL

CAS No. 1689-64-1

9-FLUORENOL( —— )

Catalog No. M22199 CAS No. 1689-64-1

9-FLUORENOL is a dopamine reuptake inhibitor with IC50 of 9 μM, and a major metabolite of a compound developed as a wakefulness-promoting agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    9-FLUORENOL
  • Note
    Research use only, not for human use.
  • Brief Description
    9-FLUORENOL is a dopamine reuptake inhibitor with IC50 of 9 μM, and a major metabolite of a compound developed as a wakefulness-promoting agent.
  • Description
    9-FLUORENOL is a dopamine reuptake inhibitor with IC50 of 9 μM, and a major metabolite of a compound developed as a wakefulness-promoting agent.Fluorenol(100 mg/kg) is reported to promote wakefulness in mice with 39% increased effectiveness over the structurally related compound, modafinil.
  • In Vitro
    ——
  • In Vivo
    Pharmacokinetic parameters of 9-Fluorenol (100 mg/kg; i.p.) in rats
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    dopamine reuptake
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1689-64-1
  • Formula Weight
    182.22
  • Molecular Formula
    C13H10O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (548.79 mM)
  • SMILES
    OC2([H])c1ccccc1c3ccccc23
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dunn D , Hostetler G , Iqbal M , et al. Wake promoting agents: Search for next generation modafinil, lessons learned: Part III[J]. Bioorganic & Medicinal Chemistry Letters, 2012, 22(11):3751-3753.
molnova catalog
related products
  • Tetrabenazine

    Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.

  • LE 300

    LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5)receptors and the serotonin 5-HT(2A)receptor.

  • SKF-83566

    SKF-83566 is a blood-brain permeable and orally active antagonist of D1-like dopamine receptor and a weaker competitive 5-HT2 receptor antagonist with Ki of 11 nMSKF-83566 caused a concentration-dependent increase in peak single-pulse evoked extracellular DA concentration, with a maximum increase of 65% in 5 μM SKF-83566.?